You just read:

Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

News provided by

Precigen, Inc.

Feb 11, 2019, 07:30 ET